000169872 001__ 169872
000169872 005__ 20240229133658.0
000169872 0247_ $$2doi$$a10.1136/bmjgast-2021-000644
000169872 0247_ $$2pmid$$apmid:34272211
000169872 0247_ $$2altmetric$$aaltmetric:109867338
000169872 037__ $$aDKFZ-2021-01606
000169872 041__ $$aEnglish
000169872 082__ $$a610
000169872 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000169872 245__ $$aSurvival in colon and rectal cancers in Finland and Sweden through 50 years.
000169872 260__ $$aLondon$$bBMJ Publishing Group$$c2021
000169872 3367_ $$2DRIVER$$aarticle
000169872 3367_ $$2DataCite$$aOutput Types/Journal article
000169872 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1626792093_14637
000169872 3367_ $$2BibTeX$$aARTICLE
000169872 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169872 3367_ $$00$$2EndNote$$aJournal Article
000169872 520__ $$aGlobal survival studies have shown favourable development in colon and rectal cancers but few studies have considered extended periods or covered populations for which medical care is essentially free of charge.We analysed colon and rectal cancer survival in Finland and Sweden over a 50-year period (1967-2016) using data from the Nordcan database. In addition to the standard 1-year and 5-year survival rates, we calculated the difference between these as a novel measure of how well survival was maintained between years 1 and 5.Relative 1-year and 5-year survival rates have developed favourably without major shifts for men and women in both countries. For Finnish men, 1-year survival in colon cancer increased from 50% to 82%, and for rectal cancer from 62% to 85%. The Swedish survival was a few per cent unit better for 1-year survival but for 5-year survival the results were equal. Survival of female patients for both cancers was somewhat better than survival in men through 50 years. Overall the survival gains were higher in the early compared with the late follow-up periods, and were the smallest in the last 10 years. The difference between 1-year and 5-year survival in colon cancer was essentially unchanged over the 50-year period while in rectal cancer there was a large improvement.The gradual positive development in survival suggests a contribution by many small improvements rather than single breakthroughs. The improvement in 5-year survival in colon cancer was almost entirely driven by improvement in 1-year survival while in rectal cancer the positive development extended to survival past year 1, probably due to successful curative treatments. The current challenges are to reinvigorate the apparently stalled positive development and to extend them to old patients. For colon cancer, survival gains need to be extended past year 1 of diagnosis.
000169872 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169872 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169872 650_7 $$2Other$$acolorectal cancer
000169872 650_7 $$2Other$$adiagnostic and therapeutic endoscopy
000169872 650_7 $$2Other$$ahealth service research
000169872 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000169872 7001_ $$aHemminki, Akseli$$b2
000169872 773__ $$0PERI:(DE-600)2884818-4$$a10.1136/bmjgast-2021-000644$$gVol. 8, no. 1, p. e000644 -$$n1$$pe000644$$tBMJ open gastroenterology$$v8$$x2054-4774$$y2021
000169872 909CO $$ooai:inrepo02.dkfz.de:169872$$pVDB
000169872 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169872 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169872 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169872 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169872 9141_ $$y2021
000169872 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-09-04
000169872 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-04
000169872 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-04
000169872 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000169872 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000169872 980__ $$ajournal
000169872 980__ $$aVDB
000169872 980__ $$aI:(DE-He78)B062-20160331
000169872 980__ $$aI:(DE-He78)HD01-20160331
000169872 980__ $$aUNRESTRICTED